Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib as adjuvant therapy after curative surgery or ablation for high-risk hepatocellular carcinoma
CTR20202509Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Hengrui Therapeutics. Started Apr 2021; status: active.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20202509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202509.